The MF Biocompatible VPP Framework — Monomer-Free Formulation as a Regulatory Engineering Strategy
This white paper presents the MF Biocompatible VPP Framework, positioning monomer-free formulation as an engineering strategy for reducing regulatory, toxicological and extractables-related risk in professional manufacturing workflows. Biocompatibility is not only a material label. It depends on formulation architecture, residual species, cleaning, post-processing, final device design, intended use, extraction behaviour and legal-manufacturer validation. MF formulation reduces one relevant risk axis within that broader pathway.
Authors
- Juan Segurola
Institutions
- Dynavax Technologies (Germany) (DE)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-08-21
- DOI
- https://doi.org/10.5281/zenodo.21973654
- Primary Topic
- Effects and risks of endocrine disrupting chemicals
- Type
- article
- Field-Weighted Citation Impact
- 0.00